Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
Key facts
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 579 people enrolled
- Started
- 15 Jun 2024
- Ended
- 10 Jan 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days
- Vonoprazan+Amoxicillin
- Vonoprazan+doxycycline
- Record updated
- 4 March 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18-65 years old
- Patients confirmed to be positive for H. pylori by 13C-UBT or 14C-UBT
- Patients who have not received Helicobacter pylori eradication therapy before, or patients who have failed to eradicate in the early stage but have not received eradication therapy within half a year
- Voluntarily join this trial and sign the informed consent form
Who cannot take part
- Patients who have received Helicobacter pylori eradication therapy within half a year
- Use of antibiotics, bismuth, and histamine H2 receptor antagonists or PPIs for the first 2 weeks before starting study treatment
- Use of adrenocorticosteroids, non-steroidal anti-inflammatory drugs, anticoagulants, barbiturates, phenytoin, or carbamazepine drugs
- Suffering from serious concomitant diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease
- Allergy to the study drug (penicillin, amoxicillin, Vonoprazan, doxycycline, etc.)
- Patients with confirmed active peptic ulcer
- History of esophageal or gastric surgery
- Hepatic insufficiency caused by hepatitis, fatty liver and other reasons
- Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant tumor diseases
- Pregnant or lactating women
- Alcoholism
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
It is planned to select Hp infection patients in a number of tertiary hospitals in Jiangsu and randomly divide them into three groups: group A is the classic group, receiving Vonoprazan 20mg, bid + amoxicillin 1.0g, bid + doxycycline 0.1g, bid + colloidal pectin bismuth 0.3g, bid and group C are double groups, respectively, receiving standard dose amoxicillin (1.0 g, bid) combined with vonorrasan dual regimen and doxycycline (0.1g, bid) combined with Vonoprazan dual regimen, the treatment course of the three groups was 14 days, and the oral dose of Vonoprazan was 20mg, bid, the eradication rate, adverse reactions, compliance and other aspects of the three groups were compared, In order to obtain a safe, efficient, economical and convenient Hp eradication program with a wider range of applications.
The 3 groups in the trial
- Group A Bismuth quadrupleExisting treatment, for comparison
Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth, treatment course 14 days
Treatment: Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days
- Group B Amoxicillin Dual therapyTreatment being tested
Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid , treatment course 14 days
Treatment: Vonoprazan+Amoxicillin
- Group C doxycycline Dual therapyTreatment being tested
Vonoprazan 20 mg, bid +doxycycline 0.1 g, bid,treatment course 14 days
Treatment: Vonoprazan+doxycycline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication:A Prospective, Multicenter, Open-label Randomized Controlled Study
- Record updated
- 4 March 2026